Vancouver, Washington-based AbSci raised $125 million in a recent funding round, bringing the company’s total funding up to $230 million. The capital will further AbSci’s growth in developing biopharmaceuticals, with a large part going toward development of the company’s newly acquired deep learning artificial intelligence platform.
“As we unlock access to novel biologies and therapeutic modalities, and work with our partners to create exciting new medicines, we are continuing to innovate and expand the scope of what we can accomplish and the impact we can have to improve human health,” said AbSci CEO and founder Sean McClain.